Ascendis Pharma A (ASND) Long-Term Debt Issuances (2022 - 2023)

Ascendis Pharma A (ASND) posted Long-Term Debt Issuances of -$3.8 million for Q4 2023, down 102.49% sequentially from $152.2 million in Q3 2023.

Ascendis Pharma A (ASND) Long-Term Debt Issuances (2022 - 2023) Analysis & Trends

Ascendis Pharma A has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$3.8 million in Q4 2023.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$3.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $148.4 million (changed 0.0% YoY) and the FY2024 annual result came in at $143.4 million, down 2.73% from the prior year.
Long-Term Debt Issuances slipped to -$3.8 million in Q4 2023 per ASND's latest filing, from $152.2 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $566.2 million in Q1 2022 and troughed at -$3.8 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-675,522.58
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Ascendis Pharma A	15.40 Bn	14.73 Bn	268.20 Mn	-

Download Data